Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 15/20 | 0.60 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31359012 | 1.00 | GPR139 (0.60) | GPR139MAPK10SMN1; SMN2LMNATSHR | |
| SCHEMBL31359079 | 0.90 | MAPK10 (0.58) | GPR139MAPK10SMN1; SMN2LMNATSHR | |
| SCHEMBL31359009 | 0.89 | GPR139 (0.56) | GPR139SMN1; SMN2MAPK1HSD17B10RXFP1 | |
| SCHEMBL31359061 | 0.89 | GPR139 (0.56) | GPR139SMN1; SMN2MAPK1HSD17B10RXFP1 | |
| SCHEMBL31359086 | 0.87 | GPR139 (0.59) | GPR139SMN1; SMN2LMNARXFP1 | |
| SCHEMBL31359013 | 0.87 | GPR139 (0.59) | GPR139SMN1; SMN2LMNARXFP1 | |
| SCHEMBL31359070 | 0.85 | GPR139 (0.49) | GPR139MAPK1HSD17B10 | |
| SCHEMBL31160967 | 0.85 | PSMD14 (0.55) | MAPK10SMN1; SMN2LMNATSHRMAPK1 | |
| SCHEMBL22686985 | 0.83 | LMNA (0.76) | MAPK10SMN1; SMN2LMNATSHRMAPK1 | |
| SCHEMBL31358967 | 0.82 | CYP1A2 (0.47) | GPR139SMN1; SMN2MAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, MYLK2 | GPR139 4045/4885MAPK10 3332/4885SMN1; SMN2 3705/4885 |
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | TNNI3, TNNT2, TNNC1 | GPR139 3566/4885MAPK10 1824/4885SMN1; SMN2 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.